Mantle D, Falkous G, Walker D
Department of Neurochemistry, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle-upon-Tyne, UK.
Clin Chim Acta. 1999 Jun 15;284(1):45-58. doi: 10.1016/s0009-8981(99)00055-8.
We have compared (using the same series of experimental samples) the levels of activity of a comprehensive range of cytoplasmic, lysosomal and matrix protease types, together with the levels of free radical-induced protein damage (determined as protein carbonyl derivative) in synovial fluid from rheumatoid (RA) and osteoarthritis (OA) cases. Many protease types showed significantly increased activity (typically by a factor of 2-3-fold) in RA compared to OA cases. Protease activity levels (including those enzyme types putatively involved in the immune response, such as dipeptidyl aminopeptidase IV) in plasma were not significantly different in RA and control cases. The level of free radical induced damage to synovial fluid proteins was approximately 2-fold higher in RA compared to OA, although there was no significant difference in total antioxidant status in synovial fluid or plasma between RA, OA or control cases. We conclude from the above that activation of proteolytic enzymes and free radicals (occurring specifically within synovial tissues) are likely to be of equal potential importance as protein damaging agents in the pathogenesis of RA, and the development of novel therapeutic strategies for the latter disorder should include both protease inhibitory and free radical scavenging elements. In addition, the protease inhibitory element should be designed to inhibit the action of a broad range of enzymic mechanistic types (cysteine, serine, metallo proteinases and peptidases).
我们(使用同一系列实验样本)比较了类风湿性关节炎(RA)和骨关节炎(OA)病例滑液中多种细胞质、溶酶体和基质蛋白酶类型的活性水平,以及自由基诱导的蛋白质损伤水平(以蛋白质羰基衍生物来测定)。与OA病例相比,许多蛋白酶类型在RA中活性显著增加(通常增加2至3倍)。RA患者与对照病例血浆中的蛋白酶活性水平(包括那些可能参与免疫反应的酶类型,如二肽基氨基肽酶IV)没有显著差异。与OA相比,RA中滑液蛋白的自由基诱导损伤水平大约高2倍,尽管RA、OA或对照病例的滑液或血浆中的总抗氧化状态没有显著差异。我们从上述情况得出结论,蛋白水解酶和自由基的激活(特别是在滑膜组织内发生)在RA发病机制中作为蛋白质损伤剂可能具有同等重要的潜在作用,并且针对后一种疾病开发新的治疗策略应包括蛋白酶抑制和自由基清除成分。此外,蛋白酶抑制成分应设计为抑制多种酶机制类型(半胱氨酸、丝氨酸、金属蛋白酶和肽酶)的作用。